Using Al18F-octreotide PET/CT for Neuroendocrine Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label study investigates the effectiveness of Al18F-octreotide PET/CT imaging in diagnosing neuroendocrine tumors. It focuses on patients with suspected or diagnosed neuroendocrine tumors, utilizing a non-invasive imaging method to enhance diagnostic accuracy. The study aims to provide clear imaging for clinical diagnosis and treatment planning, leveraging the high sensitivity and specificity of octreotide in detecting tumor cells. By employing this advanced imaging technique, the research seeks to contribute to the field of positron imaging in medicine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with suspected or clearly diagnosed SSTR positive tumors
* signed written consent.
* Willing and able to cooperate with all projects in this study.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Where it's running

• National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Chao Yang, China Recruiting

Study contacts

• Study coordinator: Gouzhu Hou, M.D.
• Email: 15611145656@163.com
• Phone: 15611145656

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Database for patients treated with metabolic radiotherapy

  This study is creating a database to collect information and samples from patients with thyroid, prostate, and neuroendocrine tumors who are receiving targeted radiation therapy, to see how it works and improve treatment.

  Recruiting at 3 sites Institut du Cancer de Montpellier - Val d'Aurelle · Bordeaux, Aquitaine and 3 other locations · NCT04104529

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer

  This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hebei, Hebei · NCT07906587

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors

  This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Shenzhen, Guangdong · NCT07865793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.